Clinical & Experimental Metastasis

, Volume 30, Issue 4, pp 483–495 | Cite as

LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice

  • Rong Li
  • Judy Doherty
  • Juliana Antonipillai
  • Sheng Chen
  • Mark Devlin
  • Kathryn Visser
  • Jonathan Baell
  • Ian Street
  • Robin L. Anderson
  • Ora Bernard
Research Paper


Metastasis is the major cause of morbidity and mortality in cancer patients. An understanding of the genes that regulate metastasis and development of therapies to target these genes is needed urgently. Since members of the LIM kinase (LIMK) family are key regulators of the actin cytoskeleton and are involved in cell motility and invasion, LIMK is considered to be a good therapeutic target for metastatic disease. Here we investigated the consequences of LIMK inhibition on growth and metastasis of human and mouse mammary tumors. LIMK activity was reduced in tumor cells by expression of dominant-negative LIMK1, by RNA interference or with a selective LIMK inhibitor. The extent of phosphorylation of the LIMK substrate, cofilin, of proliferation and invasion in 2D and 3D culture and of tumor growth and metastasis in mice were assessed. Inhibition of LIMK activity efficiently reduced the pro-invasive properties of tumor cells in vitro. Tumors expressing dominant-negative LIMK1 grew more slowly and were less metastatic in mice. However, systemic administration of a LIMK inhibitor did not reduce either primary tumor growth or spontaneous metastasis. Surprisingly, metastasis to the liver was increased after administration of the inhibitor. These data raise a concern about the use of systemic LIMK inhibitors for the treatment of metastatic breast cancer.


LIM kinase inhibitors Breast cancer Metastasis Actin cytoskeleton Therapy 



LIM kinase


Actin depolymerizing factor


Filamentous action




Small interfering RNA



We thank Christina Restall for technical assistance and advice, Dr Bala Murthy for advice on FACS analysis, Dr. Roger Tsien for provision of the cherry fluorescent protein vector, Alison Gregg and Julia Morizzi for analysis of BMS3 levels in mice, Dr. Siddhartha Deb for pathology advice and Dr. Duncan Campbell for assistance with the statistical analysis. This work was supported by grants from the NIH (R21CA098229) and from the NHMRC of Australia, Fellowship support from NHMRC (OB) and from NBCF (Australia) (RLA). The authors acknowledge financial support from the Cancer Therapeutics CRC, established and supported under the Australian Government’s Cooperative Research Centre Program.

Conflict of interest

No potential conflicts of interest were disclosed.

Supplementary material

10585_2012_9553_MOESM1_ESM.pdf (1.1 mb)
Supplementary material 1 (PDF 1158 kb)


  1. 1.
    Olson MF, Sahai E (2009) The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26:273–287PubMedCrossRefGoogle Scholar
  2. 2.
    Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465PubMedCrossRefGoogle Scholar
  3. 3.
    Wang W, Eddy R, Condeelis J (2007) The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 7:429–440PubMedCrossRefGoogle Scholar
  4. 4.
    Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7:737–749PubMedCrossRefGoogle Scholar
  5. 5.
    Bamburg JR (1999) Proteins of the ADF/cofilin family: essential regulators of actin dynamics. Annu Rev Cell Dev Biol 15:185–230PubMedCrossRefGoogle Scholar
  6. 6.
    Bamburg JR, Bernstein BW (2008) ADF/cofilin. Curr Biol 18:R273–R275PubMedCrossRefGoogle Scholar
  7. 7.
    Yamaguchi H, Condeelis J (2007) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773:642–652PubMedCrossRefGoogle Scholar
  8. 8.
    Arber S, Barbayannis FA, Hanser H et al (1998) Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393:805–809PubMedCrossRefGoogle Scholar
  9. 9.
    Yang N, Higuchi O, Ohashi K et al (1998) Cofilin phosphorylation by LIM-kinase1 and its role in Rac-mediated actin reorganization. Nature 393:809–812PubMedCrossRefGoogle Scholar
  10. 10.
    Sumi T, Matsumoto K, Takai Y et al (1999) Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2. J Cell Biol 147:1519–1532PubMedCrossRefGoogle Scholar
  11. 11.
    Bernard O (2007) LIM kinases, regulators of actin dynamics. Int J Biochem Cell Biol 39:1071–1076PubMedCrossRefGoogle Scholar
  12. 12.
    Niwa R, Nagata-Ohashi K, Takeichi M et al (2002) Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. Cell 108:233–246PubMedCrossRefGoogle Scholar
  13. 13.
    Gohla A, Birkenfeld J, Bokoch GM (2005) Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics. Nat Cell Biol 7:21–29PubMedCrossRefGoogle Scholar
  14. 14.
    Maekawa M, Ishizaki T, Boku S et al (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285:895–898PubMedCrossRefGoogle Scholar
  15. 15.
    Edwards DC, Sanders LC, Bokoch GM et al (1999) Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1:253–259PubMedCrossRefGoogle Scholar
  16. 16.
    Dan C, Kelly A, Bernard O et al (2001) Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem 276:32115–32121PubMedCrossRefGoogle Scholar
  17. 17.
    Ohashi K, Nagata K, Maekawa M et al (2000) Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 275:3577–3582PubMedCrossRefGoogle Scholar
  18. 18.
    Sumi T, Matsumoto K, Nakamura T (2001) Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 276:670–676PubMedCrossRefGoogle Scholar
  19. 19.
    Ikebe C, Ohashi K, Fujimori T et al (1997) Mouse LIM-kinase 2 gene: cDNA cloning, genomic organization, and tissue-specific expression of two alternatively initiated transcripts. Genomics 46:504–508PubMedCrossRefGoogle Scholar
  20. 20.
    Nunoue K, Ohashi K, Okano I et al (1995) LIMK-1 and LIMK-2, two members of a LIM motif-containing protein kinase family. Oncogene 11:701–710PubMedGoogle Scholar
  21. 21.
    Acevedo K, Moussi N, Li R et al (2006) LIM kinase 2 is widely expressed in all tissues. J Histochem Cytochem 54:487–501PubMedCrossRefGoogle Scholar
  22. 22.
    Davila M, Frost AR, Grizzle WE et al (2003) LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 278:36868–36875PubMedCrossRefGoogle Scholar
  23. 23.
    Saxena M, Singh S, Negi MP et al (2010) Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. J Cancer Res Ther 6:167–171PubMedCrossRefGoogle Scholar
  24. 24.
    Yoshioka K, Foletta V, Bernard O et al (2003) A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 100:7247–7252PubMedCrossRefGoogle Scholar
  25. 25.
    Bagheri-Yarmand R, Mazumdar A, Sahin AA et al (2006) LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118:2703–2710PubMedCrossRefGoogle Scholar
  26. 26.
    Scott RW, Hooper S, Crighton D et al (2010) LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol 191:169–185PubMedCrossRefGoogle Scholar
  27. 27.
    Horita Y, Ohashi K, Mukai M et al (2008) Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase. J Biol Chem 283:6013–6021PubMedCrossRefGoogle Scholar
  28. 28.
    Zebda N, Bernard O, Bailly M et al (2000) Phosphorylation of ADF/cofilin abolishes EGF-induced actin nucleation at the leading edge and subsequent lamellipod extension. J Cell Biol 151:1119–1128PubMedCrossRefGoogle Scholar
  29. 29.
    Wang W, Mouneimne G, Sidani M et al (2006) The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol 173:395–404PubMedCrossRefGoogle Scholar
  30. 30.
    Ross-Macdonald P, de Silva H, Guo Q et al (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 7:3490–3498PubMedCrossRefGoogle Scholar
  31. 31.
    Foletta VC, Moussi N, Sarmiere PD et al (2004) LIM kinase 1, a key regulator of actin dynamics, is widely expressed in embryonic and adult tissues. Exp Cell Res 294:392–405PubMedCrossRefGoogle Scholar
  32. 32.
    Lelekakis M, Moseley JM, Martin TJ et al (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17:163–170PubMedCrossRefGoogle Scholar
  33. 33.
    Barkan D, Kleinman H, Simmons JL et al (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68:6241–6250PubMedCrossRefGoogle Scholar
  34. 34.
    Lyons AB (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243:147–154PubMedCrossRefGoogle Scholar
  35. 35.
    Eckhardt BL, Parker BS, van Laar RK et al (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3:1–13PubMedGoogle Scholar
  36. 36.
    Shaw KR, Wrobel CN, Brugge JS (2004) Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9:297–310PubMedCrossRefGoogle Scholar
  37. 37.
    Korpal M, Ell BJ, Buffa FM et al (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17:1101–1108PubMedCrossRefGoogle Scholar
  38. 38.
    Harrison BA, Whitlock NA, Voronkov MV et al (2009) Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem 52:6515–6518PubMedCrossRefGoogle Scholar
  39. 39.
    Amano T, Kaji N, Ohashi K et al (2002) Mitosis-specific activation of LIM motif-containing protein kinase and roles of cofilin phosphorylation and dephosphorylation in mitosis. J Biol Chem 277:22093–22102PubMedCrossRefGoogle Scholar
  40. 40.
    Kaji N, Muramoto A, Mizuno K (2008) LIM kinase-mediated cofilin phosphorylation during mitosis is required for precise spindle positioning. J Biol Chem 283:4983–4992PubMedCrossRefGoogle Scholar
  41. 41.
    Davila M, Jhala D, Ghosh D et al (2007) Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer. Mol Cancer 6:40PubMedCrossRefGoogle Scholar
  42. 42.
    Croft DR, Olson MF (2006) The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 26:4612–4627PubMedCrossRefGoogle Scholar
  43. 43.
    Oser M, Condeelis J (2009) The cofilin activity cycle in lamellipodia and invadopodia. J Cell Biochem 108:1252–1262PubMedCrossRefGoogle Scholar
  44. 44.
    Prudent R, Vassal-Stermann E, Nguyen CH et al (2012) Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res 72(17):4429–4439PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Rong Li
    • 1
  • Judy Doherty
    • 2
    • 5
  • Juliana Antonipillai
    • 1
  • Sheng Chen
    • 1
  • Mark Devlin
    • 2
    • 5
  • Kathryn Visser
    • 2
    • 5
  • Jonathan Baell
    • 3
    • 5
  • Ian Street
    • 3
    • 5
    • 6
  • Robin L. Anderson
    • 2
    • 4
  • Ora Bernard
    • 1
    • 7
  1. 1.St Vincent’s Institute of Medical ResearchMelbourneAustralia
  2. 2.Peter MacCallum Cancer CentreMelbourneAustralia
  3. 3.The Walter and Eliza Hall Institute of Medical ResearchMelbourneAustralia
  4. 4.The Sir Peter MacCallum Department of OncologyThe University of MelbourneMelbourneAustralia
  5. 5.Cancer Therapeutics Cooperative Research CentreBundooraAustralia
  6. 6.Department of Medical BiologyThe University of MelbourneMelbourneAustralia
  7. 7.Department of MedicineThe University of Melbourne, St Vincent’s HospitalMelbourneAustralia

Personalised recommendations